Erythropoietin drugs are also known as hematopoietin. It is a glycoprotein hormone that controls erythropoiesis or production of RBC. They are used in treatment of different diseases like cancer, chronic renal diseases, AIDS, anaemia and many more. Global erythropoietin market is driven by increasing prevalence of diseases like cancer, AIDA and renal diseases. Beside this introduction of new drugs and different government initiatives for research are also has synergistic effect on growth of the market. Whereas high cost of treatment and side effects of the treatment may restrain the growth of market.
Key players for global erythropoietin drug market
Hoffmann-La Roche (Switzerland), Johnson & Johnson (US), Amgen (US), Kyowa Hakko Kirin, Intas Pharmaceuticals (India), Teva Pharmaceutical Industries Ltd. (Israel), Biocon (India), Emcure Pharmaceuticals (India), Celltrion, Inc. (South Korea), Hospira (US), Dahua Pharmaceutical (China), LG Life Sciences Ltd. (Korea), 3SBio, Boehringer Ingelheim (US), BIOSIDUS (Argentina).
Segmentation
Global erythropoietin drug market is segmented on the basis of type of product into biosimilars, first generation formulation and second generation formulation. On the basis of application market is segmented as oncology, renal diseases, HIV and other and on the basis of end user they are segmented into hospital and pharmacy.
Request Customization
Get a Sample